Monday, 31 August 2026European Markets

IDEX BIOMETRICS Skyrockets 31% As Market Outperforms

Loading stream...

(VIANEWS) - On Monday at 14:46 EST, shares of IDEX BIOMETRICS (IDEX.OL) experienced an unexpected 31.1% spike to Kr1.88, continuing an upward trend from the previous session. Meanwhile, Oslo Bors Benchmark Index_GI rose 0.65% to Kr1,301.50 as trading showed signs of strength. These developments suggest an upward trajectory in trading conditions. IDEX BIOMETRICS' last closing price was kr1.43, 73.69% below its 52-week high of kr5.45.

About IDEX BIOMETRICS

IDEX Biometrics ASA is a leading provider of fingerprint authentication solutions for various industries, such as financial payment, access control, smart cards and digital currency storage. Their products are used by manufacturers of smart cards for financial payment applications as well as biometric payment card markets. Headquartered in Oslo, Norway with global operations covering Europe, Middle East Africa Americas and Asia-Pacific regions.

Yearly Analysis

IDEX BIOMETRICS projects an estimated sales growth rate for next year of 1590.4%. This indicates that their sales should experience significant expansion during that year. However, sales growth should only be seen as one indicator of a company's financial performance and should be evaluated alongside other metrics as well as external factors like market conditions or competition that might hinder its ability to reach these projections.

Technical Analysis

IDEX BIOMETRICS (IDEX BIOMETRICS.ST) is a Danish company which specialises in designing and developing fingerprint and biometric identification technologies. Their shares are listed on the Nasdaq Copenhagen exchange. According to available information, IDEX BIOMETRICS stock is trading below its 50-day and 200-day moving averages, signalling a downward trend in its price. This may cause alarm for investors hoping for an upward trajectory in its price. However, the stock's volume is currently exceeding its average volume - this could be seen as a positive signal. An increase in volume often signals increased interest in a stock and can push its price higher. Stock volatility has fluctuated considerably in recent weeks and months, reaching its highest amplitude ever at 5.70% averaging volatility for last week, month, and quarter respectively - possibly signaling uncertainty about where this stock may head next. According to the stochastic oscillator, which serves as an indicator for overbought and oversold conditions, IDEX BIOMETRICS stock currently appears oversold (=20), suggesting it could be undervalued and likely rebound in near future. Overall, IDEX BIOMETRICS' stock is currently showing mixed signals; with its price going downward while volume increasing and an oversold condition as per stochastic oscillator; investors should carefully consider these factors when making any investment decisions.

Quarter Analysis

Quarterly Revenue Growth has declined significantly year-on-year by 54.5% to 4.14 Million since the previous 12 months.

Equity Analysis

IDEX BIOMETRICS' negative return on equity of -155.84% for the trailing twelve months suggests that they are not making profits for shareholders and is therefore raising red flags among potential investors, suggesting they may not be using shareholder capital effectively to generate profits. Before making investment decisions it's essential for potential investors to thoroughly assess a company's financial health and performance prior to making any decisions based on this figure.

More news about IDEX BIOMETRICS (IDEX.OL).

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com